Table 1.

Associations of three significant SNPs with of NSCLC overall survival in both discovery and validation datasets from two published GWASs.

SNPs	Allele a	Gene	PLCO (n=1,185)			HLCS (n=984)			Meta-analysis
			EAF	HR (95% CI) b	P b	EAF	HR (95% CI) C	P C	P het d	I 2	HR (95% CI) e	P e
rs10493829	T>C	LRRC8C	0.44	0.84 (0.76-0.93)	0.001	0.47	0.87 (0.79-0.97)	0.011	0.597	0	0.86 (0.80-0.92)	1.58x10-5
rs2239193	A>G	OAS2	0.06	1.38 (1.12-1.69)	0.002	0.06	1.23 (1.01-1.50)	0.043	0.425	0	1.30 (1.13-1.50)	3.41x10-4
rs3136651	T>A	CCL25	0.17	0.82 (0.72-0.94)	0.004	0.14	0.81 (0.70-0.95)	0.008	0.935	0	0.82 (0.74-0.90)	9.47x10-5

SNPs, single-nucleotide polymorphisms; NSCLC, non-small cell lung cancer; GWAS, genome-wide association study; PLCO, the Prostate, Lung, Colorectal and Ovarian cancer screening trial; HLCS, Harvard Lung Cancer Susceptibility Study; EAF, effect allele frequency; HR, hazards ratio; CI, confidence interval.

^aReference/effect allele.

^bAdjusted for age, sex, stage, histology, smoking status, chemotherapy, radiotherapy, surgery, identified SNPs, PC1, PC2, PC3, and PC4.

^cAdjusted for age, sex, stage, histology, smoking status, chemotherapy, radiotherapy, surgery, PC1, PC2, and PC3.

^dP_het: P value for heterogeneity by Cochrane’s Q test.

^eMeta-analysis in the fix-effects model.